Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF – Get Free Report)’s share price was up 1.9% on Monday . The stock traded as high as $13.67 and last traded at $13.64. Approximately 1,663,832 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 3,376,665 shares. The stock had previously closed at $13.39.
Mind Medicine (MindMed) Price Performance
The business has a 50-day moving average price of $12.38 and a two-hundred day moving average price of $10.63.
Mind Medicine (MindMed) Company Profile
Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.
Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.
Recommended Stories
- Five stocks we like better than Mind Medicine (MindMed)
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue
- A U.S. “birthright” claim worth trillions – activated quietly
- A Message From An Ex-CIA Officer About Trump
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.
